MYC/BCL2 Protein Co-Expression Defines a Unique Subset of Aggressive Lymphoma and Contributes to the Inferior Prognosis of Activated B-cell Subtype of Diffuse Large B-cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program Study

Shimin Hu(The University of Texas MD Anderson Cancer Center), Ken H. Young(Duke Medical Center), Michael Møller(Hospital South West Jutland), Karen Dybkær(Aalborg University Hospital), Govind Bhagat(Columbia University Irving Medical Center), Maurilio Ponzoni(San Raffaele University of Rome), Eric D. Hsi(Mayo Clinic), Ronald S. Go(Mayo Clinic), J. Han van Krieken(Radboud University Nijmegen), Zijun Y. Xu‐Monette(Duke University), Attilio Orazi(Texas Tech University), Alexandar Tzankov(University of Basel), Carlo Visco(University of Verona), Weiyun Z. Ai(City College of San Francisco), Kristy L. Richards(University of North Carolina at Chapel Hill), April Chiu(Mayo Clinic), Roberto N. Miranda(The University of Texas MD Anderson Cancer Center), Youli Zu(Methodist Hospital), Miguel Á. Piris(Hospital Universitario Fundación Jiménez Díaz), Santiago Montes‐Moreno(Universidad de Cantabria), Andrés J.M. Ferreri(Vita-Salute San Raffaele University), Lin Wu(Materials Systems (United States)), Jooryung Huh(Asan Medical Center), Xiaohong Zhang(The University of Texas MD Anderson Cancer Center), Yong Li(Baylor College of Medicine), Fan Zhou(Southwest Washington Medical Center), Xiaoying Zhao(Handan College), Qing Huang(The University of Texas MD Anderson Cancer Center), L. Jeffrey Medeiros(Delaware Division of Libraries), William W.L. Choi(Chinese University of Hong Kong), Jane N. Winter(Northwestern University)
Clinical Lymphoma Myeloma & Leukemia
September 1, 2013
Cited by 3


Related Papers